Fig. 3

MYC regulates TXNIP levels upon JQ1 treatment. The (a) mRNA and (b) protein level of MYC and TXNIP after JQ1 treatment. c The mRNA levels of MYC and TNXIP after knocking-down MYC in MOLM-14 and KG1 cells. Cells were transfected with siRNAs targeting MYC using NEON transfection system analyzed with qRT-PCR. d The protein levels of TXNIP after knocking-down MYC in MOLM-14 and KG1 cells. e KG1 cells were transfected with either pCDNA3.0 or pCDNA3-MYC vectors and treated with DMSO or JQ1 for 24 h. f The expression levels of TXNIP and MYC signature were analyzed using spearman’s correlation test. g T Dot plot of MYC signature (y-axis) and TXNIP gene expression (x-axis) in AML meta-cohort (n = 1149). Linear regression fit is shown as red dotted line. P-value is computed by Spearman correlation coefficient test. h TXNIP expression levels in AML patients alive or dead 1 year after diagnosis (0: no data available, N = 11, median = 2.47, VAR = 0.58; 1:alive after 1 year, N = 52, median = 2.96, VAR = 0.92; 2: dead after 1 year, N = 54, median = 2.58, VAR = 0.88. p = 0.0093 (1 v.s. 2, non-parameter test)